Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Do institutionals & insiders have more ownership in OCUL or BPMC?

59.2% of Ocular Therapeutix shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is OCUL or BPMC more profitable?

Blueprint Medicines has a net margin of -27.70% compared to Ocular Therapeutix's net margin of -382.51%. Blueprint Medicines' return on equity of -64.60% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-382.51%	-71.92%	-49.36%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Which has better earnings and valuation, OCUL or BPMC?

Blueprint Medicines has higher revenue and earnings than Ocular Therapeutix. Blueprint Medicines is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$63.72M	34.54	-$193.51M	-$1.28	-9.88
Blueprint Medicines	$562.12M	14.87	-$67.09M	-$2.47	-52.41

Does the media favor OCUL or BPMC?

In the previous week, Ocular Therapeutix had 13 more articles in the media than Blueprint Medicines. MarketBeat recorded 13 mentions for Ocular Therapeutix and 0 mentions for Blueprint Medicines. Ocular Therapeutix's average media sentiment score of 0.23 beat Blueprint Medicines' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Overall Sentiment
Ocular Therapeutix	Neutral
Blueprint Medicines	Neutral

Do analysts rate OCUL or BPMC?

Ocular Therapeutix currently has a consensus price target of $17.20, suggesting a potential upside of 35.97%. Blueprint Medicines has a consensus price target of $130.00, suggesting a potential upside of 0.42%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Which has more volatility & risk, OCUL or BPMC?

Ocular Therapeutix has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Summary

Ocular Therapeutix beats Blueprint Medicines on 10 of the 16 factors compared between the two stocks.